Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reaches third Alzheimer's milestone

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate.

In January 2007, Boehringer and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's nanobodies against a single disease target.

The collaboration has a potential value of $265m in upfront and milestone payments and undisclosed royalties on product sales.

Boehringer is responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Dr Edwin Moses, chairman and chief executive of Ablynx, said: "We are delighted that Boehringer Ingelheim is making further progress with the nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012."

It is the second milestone payment that Ablynx has received as part of its Alzheimer's research collaboration with Boehringer.

30th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics